Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider Sells $49,840.84 in Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 21,119 shares of Ventyx Biosciences stock in a transaction on Friday, December 27th. The shares were sold at an average price of $2.36, for a total transaction of $49,840.84. Following the completion of the sale, the insider now directly owns 464,582 shares of the company’s stock, valued at approximately $1,096,413.52. The trade was a 4.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

John Nuss also recently made the following trade(s):

• On Thursday, December 19th, John Nuss sold 13,161 shares of Ventyx Biosciences stock. The shares were sold at an average price of $2.26, for a total transaction of $29,743.86.

Ventyx Biosciences Price Performance

Shares of VTYX stock opened at $2.19 on Thursday. The firm has a 50-day moving average of $2.28 and a 200-day moving average of $2.30. Ventyx Biosciences, Inc. has a one year low of $1.67 and a one year high of $11.48. The company has a market cap of $154.86 million, a P/E ratio of -0.93 and a beta of 0.48.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on VTYX. HC Wainwright restated a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a report on Monday, November 11th. Oppenheimer reissued an “outperform” rating and set a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Institutional Investors Weigh In On Ventyx Biosciences

A number of institutional investors have recently added to or reduced their stakes in the company. Palumbo Wealth Management LLC purchased a new position in shares of Ventyx Biosciences in the 3rd quarter worth approximately $26,000. China Universal Asset Management Co. Ltd. boosted its position in Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after purchasing an additional 5,310 shares during the last quarter. Intech Investment Management LLC purchased a new position in Ventyx Biosciences in the third quarter worth $42,000. The Manufacturers Life Insurance Company grew its stake in Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after purchasing an additional 7,096 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ventyx Biosciences during the 2nd quarter valued at $58,000. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.